Neurosurgical Review

, Volume 31, Issue 2, pp 141–155

Molecular strategies for the treatment of malignant glioma—genes, viruses, and vaccines

  • Lee A. Selznick
  • Mohammed F. Shamji
  • Peter Fecci
  • Matthias Gromeier
  • Allan H. Friedman
  • John Sampson
Review
  • 156 Downloads

Abstract

The standard treatment paradigm of surgery, radiation, and chemotherapy for malignant gliomas has only a modest effect on survival. It is well emphasized in the literature that despite aggressive multimodal therapy, most patients survive approximately 1 year after diagnosis, and less than 10% survive beyond 2 years. This dismal prognosis provides the impetus for ongoing investigations in search of improved therapeutics. Standard multimodal therapy has largely reached a plateau in terms of effectiveness, and there is now a growing body of literature on novel molecular approaches for the treatment of malignant gliomas. Gene therapy, oncolytic virotherapy, and immunotherapy are the major investigational approaches that have demonstrated promise in preclinical and early clinical studies. These new molecular technologies each have distinct advantages and limitations, and none has yet demonstrated a significant survival benefit in a phase II or III clinical trial. Molecular approaches may not lead to the discovery of a “magic bullet” for these aggressive tumors, but they may ultimately prove synergistic with more conventional approaches and lead to a broadening of the multimodal approach that is the current standard of care. This review will discuss the scientific background, therapeutic potential, and clinical limitations of these novel strategies with a focus on those that have made it to clinical trials.

Keywords

Glioma Gene therapy Virotherapy Oncolytic viruses Immunotherapy 

References

  1. 1.
    Abdollahi A, Lipson KE, Sckell A, Zieher H, Klenke F, Poerschke D, Roth A, Han X, Krix M, Bischof M, Hahnfeldt P, Grone HJ, Debus J, Hlatky L, Huber PE (2003) Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects. Cancer Res 63:8890–8898PubMedGoogle Scholar
  2. 2.
    Aghi M, Chou TC, Suling K, Breakefield XO, Chiocca EA (1999) Multimodal cancer treatment mediated by a replicating oncolytic virus that delivers the oxazaphosphorine/rat cytochrome P450 2B1 and ganciclovir/herpes simplex virus thymidine kinase gene therapies. Cancer Res 59:3861–3865PubMedGoogle Scholar
  3. 3.
    Ansardi DC, Porter DC, Jackson CA, Gillespie GY, Morrow CD (2001) RNA replicons derived from poliovirus are directly oncolytic for human tumor cells of diverse origins. Cancer Res 61:8470–8479PubMedGoogle Scholar
  4. 4.
    Arafat WO, Buchsbaum DJ, Gomez-Navarro J, Tawil SA, Olsen C, Xiang J, El-Akad H, Salama AM, Badib AO, Stackhouse MA, Curiel DT (2003) An adenovirus encoding proapoptotic Bax synergistically radiosensitizes malignant glioma. Int J Radiat Oncol Biol Phys 55:1037–1050PubMedGoogle Scholar
  5. 5.
    Asaoka K, Tada M, Sawamura Y, Ikeda J, Abe H (2000) Dependence of efficient adenoviral gene delivery in malignant glioma cells on the expression levels of the coxsackievirus and adenovirus receptor. J Neurosurg 92:1002–1008PubMedGoogle Scholar
  6. 6.
    Athanassiou H, Synodinou M, Maragoudakis E, Paraskevaidis M, Verigos C, Misailidou D, Antonadou D, Saris G, Beroukas K, Karageorgis P (2005) Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme. J Clin Oncol 23:2372–2377PubMedGoogle Scholar
  7. 7.
    Baumann M, Krause M (2004) Targeting the epidermal growth factor receptor in radiotherapy: radiobiological mechanisms, preclinical and clinical results. Radiother Oncol 72:257–266PubMedGoogle Scholar
  8. 8.
    Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M, Ng L, Nye JA, Sampson-Johannes A, Fattaey A, McCormick F (1996) An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274:373–376PubMedGoogle Scholar
  9. 9.
    Bledsoe AW, Gillespie GY, Morrow CD (2000) Targeted foreign gene expression in spinal cord neurons using poliovirus replicons. J Neurovirol 6:95–105PubMedGoogle Scholar
  10. 10.
    Bogler O, Huang HJ, Kleihues P, Cavenee WK (1995) The p53 gene and its role in human brain tumors. Glia 15:308–327PubMedGoogle Scholar
  11. 11.
    Brady LW (1998) A new treatment for high grade gliomas of the brain. Bulletin et memoires de l’Academie royale de medecine de Belgique 153:255–261 discussion 261–252PubMedGoogle Scholar
  12. 12.
    Brewer CJ, Suh JH, Stevens GHJ, Barnett GH, Toms S, Vogelbaum MA, Weil R, Peereboom DM (2005) Phase II trial of erlotinib with temozolomide and concurrent radiation therapy in patients with newly-diagnosed glioblastoma multiforme. J Clin Oncol 23:1567Google Scholar
  13. 13.
    Brown PD, Maurer MJ, Rummans TA, Pollock BE, Ballman KV, Sloan JA, Boeve BF, Arusell RM, Clark MM, Buckner JC (2005) A prospective study of quality of life in adults with newly diagnosed high-grade gliomas: the impact of the extent of resection on quality of life and survival. Neurosurgery 57:495–504 discussion 495–504PubMedGoogle Scholar
  14. 14.
    Bullard DE, Gillespie GY, Mahaley MS, Bigner DD (1986) Immunobiology of human gliomas. Semin Oncol 13:94–109PubMedGoogle Scholar
  15. 15.
    Chakravarti A, Dicker A, Mehta M (2004) The contribution of epidermal growth factor receptor (EGFR) signaling pathway to radioresistance in human gliomas: a review of preclinical and correlative clinical data. Int J Radiat Oncol Biol Phys 58:927–931PubMedGoogle Scholar
  16. 16.
    Chiocca EA, Abbed KM, Tatter S, Louis DN, Hochberg FH, Barker F, Kracher J, Grossman SA, Fisher JD, Carson K, Rosenblum M, Mikkelsen T, Olson J, Markert J, Rosenfeld S, Nabors LB, Brem S, Phuphanich S, Freeman S, Kaplan R, Zwiebel J (2004) A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. Mol Ther 10:958–966PubMedGoogle Scholar
  17. 17.
    Cirielli C, Inyaku K, Capogrossi MC, Yuan X, Williams JA (1999) Adenovirus-mediated wild-type p53 expression induces apoptosis and suppresses tumorigenesis of experimental intracranial human malignant glioma. J Neurooncol 43:99–108PubMedGoogle Scholar
  18. 18.
    Cobbs CS, Harkins L, Samanta M, Gillespie GY, Bharara S, King PH, Nabors LB, Cobbs CG, Britt WJ (2002) Human cytomegalovirus infection and expression in human malignant glioma. Cancer Res 62:3347–3350PubMedGoogle Scholar
  19. 19.
    Colombo F, Barzon L, Franchin E, Pacenti M, Pinna V, Danieli D, Zanusso M, Palu G (2005) Combined HSV-TK/IL-2 gene therapy in patients with recurrent glioblastoma multiforme: biological and clinical results. Cancer Gene Ther 12:835–848PubMedGoogle Scholar
  20. 20.
    Culver KW, Ram Z, Wallbridge S, Ishii H, Oldfield EH, Blaese RM (1992) In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 256:1550–1552PubMedGoogle Scholar
  21. 21.
    Curran WJ Jr., Scott CB, Horton J, Nelson JS, Weinstein AS, Fischbach AJ, Chang CH, Rotman M, Asbell SO, Krisch RE et al (1993) Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 85:704–710PubMedGoogle Scholar
  22. 22.
    De Pace N (1912) Sulla scomparsa di un enorme cancro vegetante del collo dell’utero senza cura chirugica. Ginecologia 9:82–88Google Scholar
  23. 23.
    Doherty L, Cigas DSK, Drappatz J, Kim R, Zimmerman J, Ostrowsky L, Wen P (2006) Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas. Neurology 67:156–158PubMedGoogle Scholar
  24. 24.
    Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM, Robinson MR, Raffeld M, Duray P, Seipp CA, Rogers-Freezer L, Morton KE, Mavroukakis SA, White DE, Rosenberg SA (2002) Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298:850–854PubMedGoogle Scholar
  25. 25.
    Dudley ME, Wunderlich JR, Shelton TE, Even J, Rosenberg SA (2003) Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother 26:332–342PubMedGoogle Scholar
  26. 26.
    Dudley ME, Wunderlich JR, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry RM, Marincola FM, Leitman SF, Seipp CA, Rogers-Freezer L, Morton KE, Nahvi A, Mavroukakis SA, White DE, Rosenberg SA (2002) A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J Immunother 25:243–251PubMedGoogle Scholar
  27. 27.
    Dunn IF, Black PM (2003) The neurosurgeon as local oncologist: cellular and molecular neurosurgery in malignant glioma therapy. Neurosurgery 52:1411–1422 discussion 1422–1414PubMedGoogle Scholar
  28. 28.
    Fakhrai H, Dorigo O, Shawler DL, Lin H, Mercola D, Black KL, Royston I, Sobol RE (1996) Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy. Proc Natl Acad Sci U S A 93:2909–2914PubMedGoogle Scholar
  29. 29.
    Fecci PE, Gromeier M, Sampson JH (2002) Viruses in the treatment of brain tumors. Neuroimaging Clin N Am 12:553–570PubMedGoogle Scholar
  30. 30.
    Friese MA, Wischhusen J, Wick W, Weiler M, Eisele G, Steinle A, Weller M (2004) RNA interference targeting transforming growth factor-beta enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo. Cancer Res 64:7596–7603PubMedGoogle Scholar
  31. 31.
    Fueyo J, Alemany R, Gomez-Manzano C, Fuller GN, Khan A, Conrad CA, Liu TJ, Jiang H, Lemoine MG, Suzuki K, Sawaya R, Curiel DT, Yung WK, Lang FF (2003) Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. J Natl Cancer Inst 95:652–660PubMedCrossRefGoogle Scholar
  32. 32.
    Fueyo J, Gomez-Manzano C, Alemany R, Lee PS, McDonnell TJ, Mitlianga P, Shi YX, Levin VA, Yung WK, Kyritsis AP (2000) A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 19:2–12PubMedGoogle Scholar
  33. 33.
    Geoerger B, Grill J, Opolon P, Morizet J, Aubert G, Lecluse Y, van Beusechem VW, Gerritsen WR, Kirn DH, Vassal G (2003) Potentiation of radiation therapy by the oncolytic adenovirus dl1520 (ONYX-015) in human malignant glioma xenografts. Br J Cancer 89:577–584PubMedGoogle Scholar
  34. 34.
    Geoerger B, Grill J, Opolon P, Morizet J, Aubert G, Terrier-Lacombe MJ, Bressac De-Paillerets B, Barrois M, Feunteun J, Kirn DH, Vassal G (2002) Oncolytic activity of the E1B-55 kDa-deleted adenovirus ONYX-015 is independent of cellular p53 status in human malignant glioma xenografts. Cancer Res 62:764–772PubMedGoogle Scholar
  35. 35.
    Germano IM, Fable J, Gultekin SH, Silvers A (2003) Adenovirus/herpes simplex-thymidine kinase/ganciclovir complex: preliminary results of a phase I trial in patients with recurrent malignant gliomas. J Neurooncol 65:279–289PubMedGoogle Scholar
  36. 36.
    Gilbert MR (2006) New treatments for malignant gliomas: careful evaluation and cautious optimism required. Ann Intern Med 144:371–373PubMedGoogle Scholar
  37. 37.
    Glick RP, Lichtor T, de Zoeten E, Deshmukh P, Cohen EP (1999) Prolongation of survival of mice with glioma treated with semiallogeneic fibroblasts secreting interleukin-2. Neurosurgery 45:867–874PubMedGoogle Scholar
  38. 38.
    Gomez-Manzano C, Alonso MM, Yung WK, McCormick F, Curiel DT, Lang FF, Jiang H, Bekele BN, Zhou X, Alemany R, Fueyo J (2006) Delta-24 increases the expression and activity of topoisomerase I and enhances the antiglioma effect of irinotecan. Clin Cancer Res 12:556–562PubMedGoogle Scholar
  39. 39.
    Goudar RK, Shi Q, Hjelmeland MD, Keir ST, McLendon RE, Wikstrand CJ, Reese ED, Conrad CA, Traxler P, Lane HA, Reardon DA, Cavenee WK, Wang XF, Bigner DD, Friedman HS, Rich JN (2005) Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. Mol Cancer Ther 4:101–112PubMedGoogle Scholar
  40. 40.
    Grana C, Chinol M, Robertson C, Mazzetta C, Bartolomei M, De Cicco C, Fiorenza M, Gatti M, Caliceti P, Paganelli G (2002) Pretargeted adjuvant radioimmunotherapy with yttrium-90-biotin in malignant glioma patients: a pilot study. Br J Cancer 86:207–212PubMedGoogle Scholar
  41. 41.
    Gromeier M, Alexander L, Wimmer E (1996) Internal ribosomal entry site substitution eliminates neurovirulence in intergeneric poliovirus recombinants. Proc Natl Acad Sci U S A 93:2370–2375PubMedGoogle Scholar
  42. 42.
    Gromeier M, Bossert B, Arita M, Nomoto A, Wimmer E (1999) Dual stem loops within the poliovirus internal ribosomal entry site control neurovirulence. J Virol 73:958–964PubMedGoogle Scholar
  43. 43.
    Gromeier M, Lachmann S, Rosenfeld MR, Gutin PH, Wimmer E (2000) Intergeneric poliovirus recombinants for the treatment of malignant glioma. Proc Natl Acad Sci U S A 97:6803–6808PubMedGoogle Scholar
  44. 44.
    Gupta V, Wang W, Sosnowski BA, Hofman FM, Chen TC (2006) Fibroblast growth factor-2-retargeted adenoviral vector for selective transduction of primary glioblastoma multiforme endothelial cells. Neurosurg Focus 20:E26PubMedGoogle Scholar
  45. 45.
    Hamel W, Westphal M (2003) Gene therapy of gliomas. Acta Neurochir Suppl 88:125–135PubMedGoogle Scholar
  46. 46.
    Hanes J, Sills A, Zhao Z, Suh KW, Tyler B, DiMeco F, Brat DJ, Choti MA, Leong KW, Pardoll DM, Brem H (2001) Controlled local delivery of interleukin-2 by biodegradable polymers protects animals from experimental brain tumors and liver tumors. Pharm Res 18:899–906PubMedGoogle Scholar
  47. 47.
    Harkins L, Volk AL, Samanta M, Mikolaenko I, Britt WJ, Bland KI, Cobbs CS (2002) Specific localisation of human cytomegalovirus nucleic acids and proteins in human colorectal cancer. Lancet 360:1557–1563PubMedGoogle Scholar
  48. 48.
    Harrow S, Papanastassiou V, Harland J, Mabbs R, Petty R, Fraser M, Hadley D, Patterson J, Brown SM, Rampling R (2004) HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival. Gene Ther 11:1648–1658PubMedGoogle Scholar
  49. 49.
    Harsh GR, Deisboeck TS, Louis DN, Hilton J, Colvin M, Silver JS, Qureshi NH, Kracher J, Finkelstein D, Chiocca EA, Hochberg FH (2000) Thymidine kinase activation of ganciclovir in recurrent malignant gliomas: a gene-marking and neuropathological study. J Neurosurg 92:804–811PubMedGoogle Scholar
  50. 50.
    Heimberger AB, Crotty LE, Archer GE, Hess KR, Wikstrand CJ, Friedman AH, Friedman HS, Bigner DD, Sampson JH (2003) Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. Clin Cancer Res 9:4247–4254PubMedGoogle Scholar
  51. 51.
    Heimberger AB, Crotty LE, Archer GE, McLendon RE, Friedman A, Dranoff G, Bigner DD, Sampson JH (2000) Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma. J Neuroimmunol 103:16–25PubMedGoogle Scholar
  52. 52.
    Heise CC, Williams A, Olesch J, Kirn DH (1999) Efficacy of a replication-competent adenovirus (ONYX-015) following intratumoral injection: intratumoral spread and distribution effects. Cancer Gene Ther 6:499–504PubMedGoogle Scholar
  53. 53.
    Hilton D, Melling C (2004) Genetic markers in the assessment of intrinsic brain tumours. Curr Diagn Pathol 10:83–92Google Scholar
  54. 54.
    Holladay FP, Heitz-Turner T, Bayer WL, Wood GW (1996) Autologous tumor cell vaccination combined with adoptive cellular immunotherapy in patients with grade III/IV astrocytoma. J Neurooncol 27:179–189PubMedGoogle Scholar
  55. 55.
    Humphrey PA, Wong AJ, Vogelstein B, Friedman HS, Werner MH, Bigner DD, Bigner SH (1988) Amplification and expression of the epidermal growth factor receptor gene in human glioma xenografts. Cancer Res 48:2231–2238PubMedGoogle Scholar
  56. 56.
    Hunter WD, Martuza RL, Feigenbaum F, Todo T, Mineta T, Yazaki T, Toda M, Newsome JT, Platenberg RC, Manz HJ, Rabkin SD (1999) Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation of intracerebral injection in nonhuman primates. J Virol 73:6319–6326PubMedGoogle Scholar
  57. 57.
    Jachimczak P, Bogdahn U, Schneider J, Behl C, Meixensberger J, Apfel R, Dorries R, Schlingensiepen KH, Brysch W (1993) The effect of transforming growth factor-beta 2-specific phosphorothioate-anti-sense oligodeoxynucleotides in reversing cellular immunosuppression in malignant glioma. J Neurosurg 78:944–951PubMedGoogle Scholar
  58. 58.
    Jachimczak P, Hessdorfer B, Fabel-Schulte K, Wismeth C, Brysch W, Schlingensiepen KH, Bauer A, Blesch A, Bogdahn U (1996) Transforming growth factor-beta-mediated autocrine growth regulation of gliomas as detected with phosphorothioate antisense oligonucleotides. Int J Cancer 65:332–337PubMedGoogle Scholar
  59. 59.
    Jain RK, Baxter LT (1988) Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. Cancer Res 48:7022–7032PubMedGoogle Scholar
  60. 60.
    Johns TG, Stockert E, Ritter G, Jungbluth AA, Huang HJ, Cavenee WK, Smyth FE, Hall CM, Watson N, Nice EC, Gullick WJ, Old LJ, Burgess AW, Scott AM (2002) Novel monoclonal antibody specific for the de2–7 epidermal growth factor receptor (EGFR) that also recognizes the EGFR expressed in cells containing amplification of the EGFR gene. Int J Cancer 98:398–408PubMedGoogle Scholar
  61. 61.
    Keyt B, Liu Y, Chen F, Gudas J, Handa M, Zhang R, Senter P, Yang X (2004) Human antibody drug conjugates specific to the mutant EGF receptor (EGFRvIII) inhibit tumor growth observed with in vitro and in vivo models of glioma. Proc Am Assoc Cancer Res 45:162Google Scholar
  62. 62.
    Khazaie K, Schirrmacher V, Lichtner RB (1993) EGF receptor in neoplasia and metastasis. Cancer Metastasis Rev 12:255–274PubMedGoogle Scholar
  63. 63.
    Kikuchi T, Akasaki Y, Abe T, Fukuda T, Saotome H, Ryan JL, Kufe DW, Ohno T (2004) Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12. J Immunother 27:452–459PubMedGoogle Scholar
  64. 64.
    Klatzmann D, Valery CA, Bensimon G, Marro B, Boyer O, Mokhtari K, Diquet B, Salzmann JL, Philippon J (1998) A phase I/II study of herpes simplex virus type 1 thymidine kinase “suicide” gene therapy for recurrent glioblastoma. Study Group on Gene Therapy for Glioblastoma. Hum Gene Ther 9:2595–2604PubMedGoogle Scholar
  65. 65.
    Kock H, Harris MP, Anderson SC, Machemer T, Hancock W, Sutjipto S, Wills KN, Gregory RJ, Shepard HM, Westphal M, Maneval DC (1996) Adenovirus-mediated p53 gene transfer suppresses growth of human glioblastoma cells in vitro and in vivo. Int J Cancer 67:808–815PubMedGoogle Scholar
  66. 66.
    Komata T, Koga S, Hirohata S, Takakura M, Germano IM, Inoue M, Kyo S, Kondo S, Kondo Y (2001) A novel treatment of human malignant gliomas in vitro and in vivo: FADD gene transfer under the control of the human telomerase reverse transcriptase gene promoter. Int J Oncol 19:1015–1020PubMedGoogle Scholar
  67. 67.
    Komata T, Kondo Y, Kanzawa T, Hirohata S, Koga S, Sumiyoshi H, Srinivasula SM, Barna BP, Germano IM, Takakura M, Inoue M, Alnemri ES, Shay JW, Kyo S, Kondo S (2001) Treatment of malignant glioma cells with the transfer of constitutively active caspase-6 using the human telomerase catalytic subunit (human telomerase reverse transcriptase) gene promoter. Cancer Res 61:5796–5802PubMedGoogle Scholar
  68. 68.
    Komata T, Kondo Y, Kanzawa T, Ito H, Hirohata S, Koga S, Sumiyoshi H, Takakura M, Inoue M, Barna BP, Germano IM, Kyo S, Kondo S (2002) Caspase-8 gene therapy using the human telomerase reverse transcriptase promoter for malignant glioma cells. Hum Gene Ther 13:1015–1025PubMedGoogle Scholar
  69. 69.
    Kunwar S, Chang SM, Prados MD, Berger MS, Sampson JH, Croteau D, Sherman JW, Grahn AY, Shu VS, Dul JL, Husain SR, Joshi BH, Pedain C, Puri RK (2006) Safety of intraparenchymal convection-enhanced delivery of cintredekin besudotox in early-phase studies. Neurosurg Focus 20:E15PubMedGoogle Scholar
  70. 70.
    Kunwar S, Prados MD, Chang SM, Berger MS, Lang FF, Piepmeier JM, Sampson JH, Ram Z, Gutin PH, Gibbons RD, Aldape KD, Croteau DJ, Sherman JW, Puri RK (2007) Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. J Clin Oncol 25:837–844PubMedGoogle Scholar
  71. 71.
    Kuppner MC, Hamou MF, Sawamura Y, Bodmer S, de Tribolet N (1989) Inhibition of lymphocyte function by glioblastoma-derived transforming growth factor beta 2. J Neurosurg 71:211–217PubMedGoogle Scholar
  72. 72.
    Lamfers ML, Grill J, Dirven CM, Van Beusechem VW, Geoerger B, Van Den Berg J, Alemany R, Fueyo J, Curiel DT, Vassal G, Pinedo HM, Vandertop WP, Gerritsen WR (2002) Potential of the conditionally replicative adenovirus Ad5-Delta24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy. Cancer Res 62:5736–5742PubMedGoogle Scholar
  73. 73.
    Lammering G, Valerie K, Lin PS, Mikkelsen RB, Contessa JN, Feden JP, Farnsworth J, Dent P, Schmidt-Ullrich RK (2001) Radiosensitization of malignant glioma cells through overexpression of dominant-negative epidermal growth factor receptor. Clin Cancer Res 7:682–690PubMedGoogle Scholar
  74. 74.
    Lang FF, Bruner JM, Fuller GN, Aldape K, Prados MD, Chang S, Berger MS, McDermott MW, Kunwar SM, Junck LR, Chandler W, Zwiebel JA, Kaplan RS, Yung WK (2003) Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. J Clin Oncol 21:2508–2518PubMedGoogle Scholar
  75. 75.
    Li H, Alonso-Vanegas M, Colicos MA, Jung SS, Lochmuller H, Sadikot AF, Snipes GJ, Seth P, Karpati G, Nalbantoglu J (1999) Intracerebral adenovirus-mediated p53 tumor suppressor gene therapy for experimental human glioma. Clin Cancer Res 5:637–642PubMedGoogle Scholar
  76. 76.
    Liau LM, Black KL, Prins RM, Sykes SN, DiPatre PL, Cloughesy TF, Becker DP, Bronstein JM (1999) Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens. J Neurosurg 90:1115–1124PubMedGoogle Scholar
  77. 77.
    Lichtor T, Glick RP, Tarlock K, Moffett S, Mouw E, Cohen EP (2002) Application of interleukin-2-secreting syngeneic/allogeneic fibroblasts in the treatment of primary and metastatic brain tumors. Cancer Gene Ther 9:464–469PubMedGoogle Scholar
  78. 78.
    Lorimer IA, Keppler-Hafkemeyer A, Beers RA, Pegram CN, Bigner DD, Pastan I (1996) Recombinant immunotoxins specific for a mutant epidermal growth factor receptor: targeting with a single chain antibody variable domain isolated by phage display. Proc Natl Acad Sci U S A 93:14815–14820PubMedGoogle Scholar
  79. 79.
    Markert JM, Medlock MD, Rabkin SD, Gillespie GY, Todo T, Hunter WD, Palmer CA, Feigenbaum F, Tornatore C, Tufaro F, Martuza RL (2000) Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther 7:867–874PubMedGoogle Scholar
  80. 80.
    Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM (1991) Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 252:854–856PubMedGoogle Scholar
  81. 81.
    Medawar P (1948) Immunity to homologous grafted skin, III: the fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye. Br J Exp Pathol 29:58–69PubMedGoogle Scholar
  82. 82.
    Merrill MK, Bernhardt G, Sampson JH, Wikstrand CJ, Bigner DD, Gromeier M (2004) Poliovirus receptor CD155-targeted oncolysis of glioma. Neuro-oncol 6:208–217PubMedGoogle Scholar
  83. 83.
    Merrill MK, Gromeier M (2006) The double-stranded RNA binding protein 76:NF45 heterodimer inhibits translation initiation at the rhinovirus type 2 internal ribosome entry site. J Virol 80:6936–6942PubMedGoogle Scholar
  84. 84.
    Merritt JA, Roth JA, Logothetis CJ (2001) Clinical evaluation of adenoviral-mediated p53 gene transfer: review of INGN 201 studies. Semin Oncol 28:105–114PubMedGoogle Scholar
  85. 85.
    Michelson-Fiske S (1977) Human cytomegalovirus: a review of developments between 1970 and 1976. Part II. Experimental developments. Biomedicine 26:86–97PubMedGoogle Scholar
  86. 86.
    Mineta T, Rabkin SD, Yazaki T, Hunter WD, Martuza RL (1995) Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1:938–943PubMedGoogle Scholar
  87. 87.
    Moolten FL (1986) Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res 46:5276–5281PubMedGoogle Scholar
  88. 88.
    Morral N, O’Neal W, Zhou H, Langston C, Beaudet A (1997) Immune responses to reporter proteins and high viral dose limit duration of expression with adenoviral vectors: comparison of E2a wild type and E2a deleted vectors. Hum Gene Ther 8:1275–1286PubMedGoogle Scholar
  89. 89.
    Moscatello DK, Holgado-Madruga M, Godwin AK, Ramirez G, Gunn G, Zoltick PW, Biegel JA, Hayes RL, Wong AJ (1995) Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res 55:5536–5539PubMedGoogle Scholar
  90. 90.
    Ni HT, Spellman SR, Jean WC, Hall WA, Low WC (2001) Immunization with dendritic cells pulsed with tumor extract increases survival of mice bearing intracranial gliomas. J Neurooncol 51:1–9PubMedGoogle Scholar
  91. 91.
    Owens T, Renno T, Taupin V, Krakowski M (1994) Inflammatory cytokines in the brain: does the CNS shape immune responses? Immunol Today 15:566–571PubMedGoogle Scholar
  92. 92.
    Paganelli G, Grana C, Chinol M, Cremonesi M, De Cicco C, De Braud F, Robertson C, Zurrida S, Casadio C, Zoboli S, Siccardi AG, Veronesi U (1999) Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin. Eur J Nucl Med 26:348–357PubMedGoogle Scholar
  93. 93.
    Papanastassiou V, Rampling R, Fraser M, Petty R, Hadley D, Nicoll J, Harland J, Mabbs R, Brown M (2002) The potential for efficacy of the modified (ICP 34.5(−)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study. Gene Ther 9:398–406PubMedGoogle Scholar
  94. 94.
    Parajuli P, Mathupala S, Sloan AE (2004) Systematic comparison of dendritic cell-based immunotherapeutic strategies for malignant gliomas: in vitro induction of cytolytic and natural killer-like T cells. Neurosurgery 55:1194–1204PubMedGoogle Scholar
  95. 95.
    Parney IF, Chang LJ, Farr-Jones MA, Hao C, Smylie M, Petruk KC (2006) Technical hurdles in a pilot clinical trial of combined B7-2 and GM-CSF immunogene therapy for glioblastomas and melanomas. J Neurooncol 78:71–80PubMedGoogle Scholar
  96. 96.
    Parney IF, Farr-Jones MA, Chang LJ, Petruk KC (2000) Human glioma immunobiology in vitro: implications for immunogene therapy. Neurosurgery 46:1169–1177 discussion 1177–1168PubMedGoogle Scholar
  97. 97.
    Parney IF, Farr-Jones MA, Kane K, Chang LJ, Petruk KC (2002) Human autologous in vitro models of glioma immunogene therapy using B7-2, GM-CSF, and IL12. Can J Neurol Sci 29:267–275PubMedGoogle Scholar
  98. 98.
    Parney IF, Farr-Jones MA, Koshal A, Chang LJ, Petruk KC (2002) Human brain tumor cell culture characterization after immunostimulatory gene transfer. Neurosurgery 50:1094–1102PubMedGoogle Scholar
  99. 99.
    Plautz GE, Miller DW, Barnett GH, Stevens GH, Maffett S, Kim J, Cohen PA, Shu S (2000) T cell adoptive immunotherapy of newly diagnosed gliomas. Clin Cancer Res 6:2209–2218PubMedGoogle Scholar
  100. 100.
    Prados MD, McDermott M, Chang SM, Wilson CB, Fick J, Culver KW, Van Gilder J, Keles GE, Spence A, Berger M (2003) Treatment of progressive or recurrent glioblastoma multiforme in adults with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration: a phase I/II multi-institutional trial. J Neurooncol 65:269–278PubMedGoogle Scholar
  101. 101.
    Prins RM, Graf MR, Merchant RE (2001) Cytotoxic T cells infiltrating a glioma express an aberrant phenotype that is associated with decreased function and apoptosis. Cancer Immunol Immunother 50:285–292PubMedGoogle Scholar
  102. 102.
    Quattrocchi KB, Miller CH, Cush S, Bernard SA, Dull ST, Smith M, Gudeman S, Varia MA (1999) Pilot study of local autologous tumor infiltrating lymphocytes for the treatment of recurrent malignant gliomas. J Neurooncol 45:141–157PubMedGoogle Scholar
  103. 103.
    Rainov NG (2000) A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum Gene Ther 11:2389–2401PubMedGoogle Scholar
  104. 104.
    Rainov NG, Heidecke V (2004) Long term survival in a patient with recurrent malignant glioma treated with intratumoral infusion of an IL4-targeted toxin (NBI-3001). J Neurooncol 66:197–201PubMedGoogle Scholar
  105. 105.
    Rainov NG, Ren H (2003) Oncolytic viruses for treatment of malignant brain tumours. Acta Neurochir Suppl 88:113–123PubMedGoogle Scholar
  106. 106.
    Ram Z, Culver KW, Oshiro EM, Viola JJ, DeVroom HL, Otto E, Long Z, Chiang Y, McGarrity GJ, Muul LM, Katz D, Blaese RM, Oldfield EH (1997) Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat Med 3:1354–1361PubMedGoogle Scholar
  107. 107.
    Rampling R, Cruickshank G, Papanastassiou V, Nicoll J, Hadley D, Brennan D, Petty R, MacLean A, Harland J, McKie E, Mabbs R, Brown M (2000) Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther 7:859–866PubMedGoogle Scholar
  108. 108.
    Ratcheson RA (2005) Fast forwarding: the evolution of neurosurgery. The 2005 presidential address. J Neurosurg 103:585–590PubMedCrossRefGoogle Scholar
  109. 109.
    Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE 2nd, Cokgor I, McLendon RE, Pegram CN, Provenzale JM, Quinn JA, Rich JN, Regalado LV, Sampson JH, Shafman TD, Wikstrand CJ, Wong TZ, Zhao XG, Zalutsky MR, Bigner DD (2002) Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol 20:1389–1397PubMedGoogle Scholar
  110. 110.
    Reardon DA, Egorin MJ, Quinn JA, Rich JN, Gururangan S, Vredenburgh JJ, Desjardins A, Sathornsumetee S, Provenzale JM, Herndon JE 2nd, Dowell JM, Badruddoja MA, McLendon RE, Lagattuta TF, Kicielinski KP, Dresemann G, Sampson JH, Friedman AH, Salvado AJ, Friedman HS (2005) Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J Clin Oncol 23:9359–9368PubMedGoogle Scholar
  111. 111.
    Rich J, Reardon DA, Quinn JA, Vredenburgh J, Desjardins A, Sathornsumetee S, Gururangan S, Lyons P, Bigner DD, Friedman HS (2005) A phase I trail of gefitinib (Ireassa; ZD1839) plus rapamycin for patients with recurrent malignant glioma. J Clin Oncol 23:1565Google Scholar
  112. 112.
    Rubinchik S, Yu H, Woraratanadharm J, Voelkel-Johnson C, Norris JS, Dong JY (2003) Enhanced apoptosis of glioma cell lines is achieved by co-delivering FasL-GFP and TRAIL with a complex Ad5 vector. Cancer Gene Ther 10:814–822PubMedGoogle Scholar
  113. 113.
    Rustamzadeh E, Low WC, Vallera DA, Hall WA (2003) Immunotoxin therapy for CNS tumor. J Neurooncol 64:101–116PubMedGoogle Scholar
  114. 114.
    Rutkowski S, De Vleeschouwer S, Kaempgen E, Wolff JE, Kuhl J, Demaerel P, Warmuth-Metz M, Flamen P, Van Calenbergh F, Plets C, Sorensen N, Opitz A, Van Gool SW (2004) Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study. Br J Cancer 91:1656–1662PubMedGoogle Scholar
  115. 115.
    Samanta M, Harkins L, Klemm K, Britt WJ, Cobbs CS (2003) High prevalence of human cytomegalovirus in prostatic intraepithelial neoplasia and prostatic carcinoma. J Urol 170:998–1002PubMedGoogle Scholar
  116. 116.
    Sandmair AM, Loimas S, Puranen P, Immonen A, Kossila M, Puranen M, Hurskainen H, Tyynela K, Turunen M, Vanninen R, Lehtolainen P, Paljarvi L, Johansson R, Vapalahti M, Yla-Herttuala S (2000) Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses. Hum Gene Ther 11:2197–2205PubMedGoogle Scholar
  117. 117.
    Shand N, Weber F, Mariani L, Bernstein M, Gianella-Borradori A, Long Z, Sorensen AG, Barbier N (1999) A phase 1–2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir. GLI328 European–Canadian Study Group. Hum Gene Ther 10:2325–2335PubMedGoogle Scholar
  118. 118.
    Shimamura T, Husain SR, Puri RK (2006) The IL-4 and IL-13 pseudomonas exotoxins: new hope for brain tumor therapy. Neurosurg Focus 20:E11PubMedGoogle Scholar
  119. 119.
    Simpson JR, Horton J, Scott C, Curran WJ, Rubin P, Fischbach J, Isaacson S, Rotman M, Asbell SO, Nelson JS et al (1993) Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. Int J Radiat Oncol Biol Phys 26:239–244PubMedGoogle Scholar
  120. 120.
    Sissons JG, Carmichael AJ (2002) Clinical aspects and management of cytomegalovirus infection. J Infect 44:78–83PubMedGoogle Scholar
  121. 121.
    Skornick Y, Topalian S, Rosenberg SA (1990) Comparative studies of the long-term growth of lymphocytes from tumor infiltrates, tumor-draining lymph nodes, and peripheral blood by repeated in vitro stimulation with autologous tumor. J Biol Response Mod 9:431–438PubMedGoogle Scholar
  122. 122.
    Sloan KE, Stewart JK, Treloar AF, Matthews RT, Jay DG (2005) CD155/PVR enhances glioma cell dispersal by regulating adhesion signaling and focal adhesion dynamics. Cancer Res 65:10930–10937PubMedGoogle Scholar
  123. 123.
    Smitt PS, Driesse M, Wolbers J, Kros M, Avezaat C (2003) Treatment of relapsed malignant glioma with an adenoviral vector containing the herpes simplex thymidine kinase gene followed by ganciclovir. Mol Ther 7:851–858PubMedGoogle Scholar
  124. 124.
    Song Y, Friebe P, Tzima E, Junemann C, Bartenschlager R, Niepmann M (2006) The hepatitis C virus RNA 3′-untranslated region strongly enhances translation directed by the internal ribosome entry site. J Virol 80:11579–11588PubMedGoogle Scholar
  125. 125.
    Stevens A, Kloter I, Roggendorf W (1988) Inflammatory infiltrates and natural killer cell presence in human brain tumors. Cancer 61:738–743PubMedGoogle Scholar
  126. 126.
    Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996PubMedGoogle Scholar
  127. 127.
    Sugawa N, Ueda S, Nakagawa Y, Nishino H, Nosaka K, Iwashima A, Kurimoto M (1998) An antisense EGFR oligodeoxynucleotide enveloped in Lipofectin induces growth inhibition in human malignant gliomas in vitro. J Neurooncol 39:237–244PubMedGoogle Scholar
  128. 128.
    Takeuchi H, Kanzawa T, Kondo Y, Komata T, Hirohata S, Kyo S, Kondo S (2004) Combination of caspase transfer using the human telomerase reverse transcriptase promoter and conventional therapies for malignant glioma cells. Int J Oncol 25:57–63PubMedGoogle Scholar
  129. 129.
    Trask TW, Trask RP, Aguilar-Cordova E, Shine HD, Wyde PR, Goodman JC, Hamilton WJ, Rojas-Martinez A, Chen SH, Woo SL, Grossman RG (2000) Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors. Mol Ther 1:195–203PubMedGoogle Scholar
  130. 130.
    Tripathy SK, Black HB, Goldwasser E, Leiden JM (1996) Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors. Nat Med 2:545–550PubMedGoogle Scholar
  131. 131.
    Tyminski E, Leroy S, Terada K, Finkelstein DM, Hyatt JL, Danks MK, Potter PM, Saeki Y, Chiocca EA (2005) Brain tumor oncolysis with replication-conditional herpes simplex virus type 1 expressing the prodrug-activating genes, CYP2B1 and secreted human intestinal carboxylesterase, in combination with cyclophosphamide and irinotecan. Cancer Res 65:6850–6857PubMedGoogle Scholar
  132. 132.
    Van den Bent MJ, Stupp R, Mason WP (2005) Impact of extent of resection on overall survival in newly-diagnosed glioblastoma after chemo-irradiation with temozolomide: further analysis of EORTC study 26981. Eur J Cancer Suppl 3:134Google Scholar
  133. 133.
    Vecil GG, Lang FF (2003) Clinical trials of adenoviruses in brain tumors: a review of Ad-p53 and oncolytic adenoviruses. J Neurooncol 65:237–246PubMedGoogle Scholar
  134. 134.
    Wang MY, Lu KV, Zhu S, Dia EQ, Vivanco I, Shackleford GM, Cavenee WK, Mellinghoff IK, Cloughesy TF, Sawyers CL, Mischel PS (2006) Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. Cancer Res 66:7864–7869PubMedGoogle Scholar
  135. 135.
    Wang X, Huong SM, Chiu ML, Raab-Traub N, Huang ES (2003) Epidermal growth factor receptor is a cellular receptor for human cytomegalovirus. Nature 424:456–461PubMedGoogle Scholar
  136. 136.
    Watanabe K, Tachibana O, Sata K, Yonekawa Y, Kleihues P, Ohgaki H (1996) Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 6:217–223 discussion 223–214PubMedGoogle Scholar
  137. 137.
    Weber F, Asher A, Bucholz R, Berger M, Prados M, Chang S, Bruce J, Hall W, Rainov NG, Westphal M, Warnick RE, Rand RW, Floeth F, Rommel F, Pan H, Hingorani VN, Puri RK (2003) Safety, tolerability, and tumor response of IL4-Pseudomonas exotoxin (NBI-3001) in patients with recurrent malignant glioma. J Neurooncol 64:125–137PubMedGoogle Scholar
  138. 138.
    Wikstrand CJ, McLendon RE, Friedman AH, Bigner DD (1997) Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII. Cancer Res 57:4130–4140PubMedGoogle Scholar
  139. 139.
    Yamanaka R, Homma J, Yajima N, Tsuchiya N, Sano M, Kobayashi T, Yoshida S, Abe T, Narita M, Takahashi M, Tanaka R (2005) Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial. Clin Cancer Res 11:4160–4167PubMedGoogle Scholar
  140. 140.
    Yu JS, Liu G, Ying H, Yong WH, Black KL, Wheeler CJ (2004) Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res 64:4973–4979PubMedGoogle Scholar
  141. 141.
    Zafiropoulos A, Tsentelierou E, Billiri K, Spandidos DA (2003) Human herpes viruses in non-melanoma skin cancers. Cancer Lett 198:77–81PubMedGoogle Scholar
  142. 142.
    Zhang Y, Zhu C, Pardridge WM (2002) Antisense gene therapy of brain cancer with an artificial virus gene delivery system. Mol Ther 6:67–72PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Lee A. Selznick
    • 1
  • Mohammed F. Shamji
    • 2
    • 3
    • 5
  • Peter Fecci
    • 4
  • Matthias Gromeier
    • 1
  • Allan H. Friedman
    • 1
  • John Sampson
    • 1
  1. 1.Division of NeurosurgeryDuke University Medical CenterDurhamUSA
  2. 2.Division of NeurosurgeryThe Ottawa HospitalOttawaCanada
  3. 3.Department of Biomedical EngineeringDuke UniversityDurhamUSA
  4. 4.Duke University School of MedicineDurhamUSA
  5. 5.DurhamUSA

Personalised recommendations